Contrasting Tarsus Pharmaceuticals (TARS) & Its Peers

Tarsus Pharmaceuticals (NASDAQ:TARS) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Tarsus Pharmaceuticals to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings.

Profitability

This table compares Tarsus Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-102.93%	-24.51%	-12.40%
Tarsus Pharmaceuticals Competitors	-2,381.29%	-218.58%	-15.77%

Analyst Ratings

This is a summary of current ratings for Tarsus Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1	1	7	1	2.80
Tarsus Pharmaceuticals Competitors	7777	13864	25753	1034	2.41

Tarsus Pharmaceuticals currently has a consensus target price of $104.57, indicating a potential upside of 54.87%. As a group, “Pharmaceuticals” companies have a potential upside of 24.63%. Given Tarsus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Tarsus Pharmaceuticals is more favorable than its competitors.

Risk & Volatility

Tarsus Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals’ competitors have a beta of -4.12, suggesting that their average share price is 512% less volatile than the S&P 500.

Institutional & Insider Ownership

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Tarsus Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tarsus Pharmaceuticals	$682.20 million	-$66.42 million	-4.45
Tarsus Pharmaceuticals Competitors	$4.32 billion	$3.15 billion	548.20

Tarsus Pharmaceuticals’ competitors have higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Tarsus Pharmaceuticals beats its competitors on 9 of the 13 factors compared.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.